Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
GC-101 by Shanghai Juncell Therapeutics for Cervical Cancer: Likelihood of Approval
GC-101 is under clinical development by Shanghai Juncell Therapeutics and currently in Phase I for Cervical Cancer. According to GlobalData,...
GC-203 by Shanghai Juncell Therapeutics for Metastatic Ovarian Cancer: Likelihood of Approval
GC-203 is under clinical development by Shanghai Juncell Therapeutics and currently in Phase I for Metastatic Ovarian Cancer. According to...
GC-101 by Shanghai Juncell Therapeutics for Metastatic Melanoma: Likelihood of Approval
GC-101 is under clinical development by Shanghai Juncell Therapeutics and currently in Phase II for Metastatic Melanoma. According to GlobalData,...